



## **Verrica Pharmaceuticals Announces Participation in the 21<sup>st</sup> Annual Needham Virtual Healthcare Conference**

WEST CHESTER, PA – April 7, 2022 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21<sup>st</sup> Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m. ET.

Participants may access a live webcast of the event through the following link:

<https://wsw.com/webcast/needham117/vrca/2246788>.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at [www.verrica.com](http://www.verrica.com). The webcast replay will be available shortly after conclusion of the event for 30 days.

### **About Verrica Pharmaceuticals Inc.**

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit [www.verrica.com](http://www.verrica.com).

### **FOR MORE INFORMATION, PLEASE CONTACT:**

Investors:

#### **William Windham**

Solebury Trout

646.378.2946

[wwindham@soleburytrout.com](mailto:wwindham@soleburytrout.com)

#### **Terry Kohler**

Chief Financial Officer

484.453.3296

[info@verrica.com](mailto:info@verrica.com)

Media:

**Zara Lockshin**

Solebury Trout

646.378.2960

[zlockshin@soleburytrout.com](mailto:zlockshin@soleburytrout.com)